Our STN: BL 125251/382

SUPPLEMENT APPROVAL
December 1, 2023

OCTAPHARMA Pharmazeutika Produktionsges.m.b.H.
Attention: Stanley Ammons
Octapharma USA, Inc.
117 West Century Road
Paramus, NJ 07652

Dear Mr. Ammons:

We have approved your request received February 1, 2023, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for von Willebrand Factor/Coagulation Factor VIII Complex (Human) to expand the indication in children 6 years of age and older and adult patients with von Willebrand disease (VWD) to include routine prophylaxis to reduce the frequency of bleeding episodes.

The review of this supplement was associated with the following National Clinical Trial (NCT) numbers: NCT04052698 and NCT04953884.

LABELING

We hereby approve the draft content of labeling Package Insert, Patient Package Insert, and Instructions for Use submitted under amendment 19, dated December 1, 2023.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert, Patient Package Insert, and Instructions for Use submitted on December 1, 2023. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125251 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these changes.

PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for birth to less than 2 years of age because necessary studies are impossible or highly impracticable. This is because the number of pediatric patients is small or geographically dispersed. Additionally, many children with VWD are not typically exposed to prophylaxis in this age group.

We are deferring submission of your pediatric study for ages 2 years to less than 6 years of age for this application because this product is ready for approval for use in adults and the pediatric study has not been completed.

Your deferred pediatric study required under section 505B(a) of the Federal Food, Drug, and Cosmetic Act (FDCA) is a required postmarketing study. The status of this postmarketing study must be reported according to 21 CFR 601.28 and section 505B(a)(3)(B) of the FDCA. In addition, section 506B of the FDCA and 21 CFR 601.70 require you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

Label your annual report as an **Annual Status Report of Postmarketing Study Requirement/Commitments** and submit it to the FDA each year within 60 calendar days of the anniversary date of the approval of BLA STN BL 125251 until all requirements and commitments subject to the reporting requirements under section 506B of the FDCA are released or fulfilled. This required study is listed below:

1. Deferred pediatric study under PREA for the treatment of routine prophylaxis in pediatric patients with VWD ages 2 to less than 6 years of age.

   Final Protocol Submission: February 2021

   Study Completion Date: May 2024

   Final Report Submission: December 2024

Submit the protocol to your IND 11303, with a cross-reference letter to BLA, STN BL 125251 explaining that this protocol was submitted to the IND.

Submit final study reports to this BLA, STN BL 125251. In order for your PREA PMR to be considered fulfilled, you must submit and receive approval of either an efficacy or a labeling supplement. For administrative purposes, all submissions related to this required pediatric postmarketing study must be clearly designated as:

- **Required Pediatric Assessment**

This product is appropriately labeled for use in children and adolescents 6 to 17 years of age for this indication. Therefore, no additional studies are needed in this pediatric group.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Nicole Verdun, MD
Acting Director
Division of Clinical Evaluation Hematology
Office of Clinical Evaluation
Office of Therapeutic Products
Center for Biologics Evaluation and Research